Sweden’s Xbrane Biopharma has revealed that it is to cease development of a Keytruda (pembrolizumab) biosimilar as it looks to break even by early 2025. At the same time, the firm has announced plans to cut 40 staff as part of a cost-savings scheme aimed at saving the company around SEK50m ($5m) annually.
Xbrane had revealed at the end of 2021 that it had initiated development for a pair of new biosimilar candidates, referencing Keytruda
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?